Pharma POOL Dr. Mahdi B. Fawzi Dr. Frank S. Walsh Wyeth Promotes Two Research Scientists to Executive VPs Wyeth Pharmaceuticals, Madison, N.J., a division of Wyeth, has promoted Mahdi B. Fawzi, Ph.D., to executive VP, head of preclinical development, and Frank S. Walsh, Ph.D., to executive VP, head of discovery research. Wyeth is one of the world’s largest research-driven pharmaceutical and healthcare products companies. Dr. Fawzi, who had been senior VP of chemical and pharmaceutical development (CPD), heads up the newly created preclinical development department, which combines the drug safety and metabolism (DSM) and CPD organizations. Dr. Fawzi received his Ph.D. in pharmaceutical chemistry from the University of Michigan. Dr. Walsh joined Wyeth in 2002 as senior VP, head of discovery research. In addition to his current responsibilities, Dr. Walsh oversees a newly organized translational research group to optimize the transition of products leaving discovery research and entering clinical development. Dr. Walsh received his Ph.D. in biochemistry from University College, London, followed by a postdoctoral research fellowship at the National Institutes of Health. Lori Moore Joe Young Novo Nordisk Announces Two Key U.S. Appointments Novo Nordisk has created two key positions in the United States intended to help accelerate the company’s growth and presence in this market. Novo Nordisk, based in Denmark with U.S. headquarters in Princeton, N.J., is a healthcare company and a world leader in diabetes care. Lori Moore has been appointed executive director of corporate branding and communications. In this newly created position, Ms. Moore develops the company’s overall corporate communications strategy, integrating corporate branding, public affairs, media relations, strategic advocacy, brand public relations, and employee communications programs. Before joining Novo Nordisk, Ms. Moore worked for Aventis Pharmaceuticals as director of U.S. commercial communications and media relations. Ms. Moore holds a master of science degree in communications from Northwestern University and a bachelor of arts degree in journalism from Northern Illinois University. Joe Young has been named associate VP of diabetes brand leadership. Mr. Young’s new responsibilities include leading diabetes brand management, which includes the brand teams, new products, commercial medical-education activities, brand-information support, and marketing logistics. He joins Novo Nordisk after five years at Aventis Pharmaceuticals, where most recently he served as the global marketing leader for a worldwide diabetes product launch. Mr. Young received a bachelor of science degree from Texas A&M University. Gail S. Thornton Schering-Plough Names Communications VP Schering-Plough has named Gail S. Thornton VP, global communications, Europe, Canada, Middle East, Africa, Japan, Latin America, and Far East regions. Schering-Plough is a global science-based healthcare company with leading prescription, consumer, and animal-health products. Ms. Thornton, based in the company’s Kenilworth, N.J., headquarters, is building the global communications function to include a world-class communications network. Her additional areas of responsibility include creating a presence for media and advocacy relations and also working cross-functionally with communications colleagues in the company’s country operations. Most recently, Ms. Thornton was a communications consultant for Schering-Plough and had been responsible for internal and external communications in international market countries. She holds a B.A. degree in journalism from Rider University and a M.A. degree in diplomacy and international relations from The John C. Whitehead School of Diplomacy and International Relations at Seton Hall University. She is currently completing a Ph.D. degree in health sciences at Seton Hall University. Biotech POOL Dr. Willard Dere Amgen Names Global Development VP and Chief Medical Officer Amgen, a Thousand Oaks, Calif.-based biotechnology company, has appointed Willard Dere, M.D., to the position of senior VP of global development. In addition, Dr. Dere has been named Amgen’s chief medical officer. Dr. Dere, formerly VP and head of general medicine at Amgen, is responsible for leading Amgen’s development organization. He replaces Beth Seidenberg, M.D., who has left Amgen to pursue other career interests. Dr. Dere joined Amgen in 2003 as VP and head of the inflammation therapeutic area. He received his medical and undergraduate degrees from the University of California at Davis. He has served on committees of several professional organizations, including The Pharmaceutical Research and Manufacturers of America, the American Society of Bone and Mineral Research, and the Group for Respect, Excellence and Ethics in Science. Dr. Charles S. Swindell Phyton Biotech Hires R&D VP Phyton Biotech, a DFB Pharmaceuticals affiliate, has hired Charles S. Swindell, Ph.D., as VP of research and development. Based in Ithaca, N.Y., Phyton Biotech specializes in the use of plant cell culture technology. Dr. Swindell plays a key role in further developing Phyton as a fully integrated biotechnology company with a complete range of capabilities, from R&D through manufacturing and marketing. Dr. Swindell previously served as senior VP of research and development for Protarga. He received a B.S. in chemistry from the University of Houston (Texas), and a Ph.D. in organic chemistry from Rice University. Dr. Swindell was a Swiss National Science Foundation postdoctoral fellow at the ETH-Zurich. He is a member of the American Chemical Society and the American Society of Pharmacognosy. Biopharmaceutical POOL Dr. David Apelian Kirk Christoffersen GlobeImmune Announces Management Appointments GlobeImmune, Aurora, Colo., an early-stage biopharmaceutical company pioneering the development of potent, targeted molecular immunotherapies for the treatment of cancer and infectious diseases, has named David Apelian, M.D., Ph.D., MBA, to the position of VP of clinical development and regulatory affairs and chief medical officer. Dr. Apelian previously served at Bristol-Myers Squibb as clinical director in the department of clinical design and evaluation/infectious diseases group and medical lead for clinical development for the NDA filing of entecavir for chronic HBV. Dr. Apelian received a Ph.D. in biochemistry from Rutgers University, a M.D. from the University of Medicine and Dentistry of New Jersey, and a MBA from Quinnipiac University. Kirk Christoffersen, MBA, has been named senior director, corporate development. He has more than eight years of experience in biotechnology-related corporate development and marketing and, most recently, served as Gelclair brand leader at OSI Pharmaceuticals. Jeffrey H. Buchalter Enzon Names President and CEO Jeffrey H. Buchalter has been named president and CEO of Enzon Pharmaceuticals, a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat life-threatening diseases. Mr. Buchalter, 47, continues as chairman of Enzon’s board of directors, a position he assumed in September 2004. Before joining Enzon, Bridgewater, N.J., Mr. Buchalter served as president, CEO, and director of Ilex Oncology. He received a bachelor of science degree in finance from Seton Hall University and a MBA in marketing from Temple University. Dr. Ton Bunt Oscient Hires Senior VP, Clinical Development Oscient Pharmaceuticals has named Ton Bunt, M.D., Ph.D., to the position of senior VP, clinical development and medical affairs. Oscient is a biopharmaceutical company committed to the clinical development and commercialization of novel therapeutics to address unmet medical needs. At Oscient, Waltham, Mass., Dr. Bunt is responsible for directing new product development, clinical development, and regulatory affairs, as well as for collaborating on commercialization strategies, in-licensing activities, and scientific communications. Dr. Gary Patou, Oscient’s chief medical officer, is working closely with Dr. Bunt. Beginning in April, Dr. Patou will be a key consultant to Oscient. Dr. Bunt has more than 20 years of healthcare experience, having spent 10 years in the pharmaceutical industry serving in increasingly strategic roles at Merck and Novartis. Previously he was senior medical director of Merck’s hypertension group and group medical officer of corporate marketing at Novartis. He received a M.D. from the University of Leiden in The Netherlands, a Ph.D. from the University of Leiden, and a MBA from the Wharton School at the University of Pennsylvania. Dr. Ed Cannon AdipoGenix Appoints President and CEO AdipoGenix, a biopharmaceutical company developing products that treat obesity and its comorbidities, has named Ed Cannon, Ph.D., president and CEO. Tom Vogel, who joined the company as president and CEO in 2002, continues with AdipoGenix as an advisor and member of the board. Dr. Cannon is seeking Series A financing to fund AdipoGenix’s advancement of a proprietary compound into the clinic and to fuel continued progress in the company’s internal discovery programs, its partnership with Johnson & Johnson Pharmaceuticals, as well as strategic business development and licensing activities. Before joining Boston-based AdipoGenix, Dr. Cannon was founding president and CEO of Elixir Pharmaceuticals. He trained in molecular immunology at Harvard Medical School and has held faculty positions at Brandeis University and University of Massachusetts Medical School. Robert Doman DUSA Appoints President and Chief Operating Officer Robert Doman has been appointed president and chief operating officer of DUSA Pharmaceuticals, a biopharmaceutical company based in Wilmington, Mass. Mr. Doman has more than 25 years of experience in the medical-device industry and served from 2000 until 2004 as president of Leach Technology Group. Ann Neale Saegis Pharmaceuticals Selects Clinical Operations VP Saegis Pharmaceuticals, a biopharmaceutical company focused on developing medicines that protect and enhance memory and cognition, has appointed Ann Neale as VP of clinical operations. In this newly created role, Ms. Neale is responsible for the strategic oversight of Saegis’ clinical-development programs. Ms. Neale brings to Saegis, Half Moon Bay, Calif., more than 15 years of experience in the clinical design and development area with expertise in managing complex clinical programs across multiple therapeutic areas. Before joining Saegis, Ms. Neale was the senior director of development planning and operations for ARYx Therapeutics. Ms. Neale has clinical experience in critical care and holds a B.S. degree in nursing from the University of Minnesota. Specialty POOL Harry Carmitchel Osiris Therapeutics Strengthens Executive Team Baltimore-based Osiris Therapeutics, which specializes in adult stem-cell therapy, has named Harry Carmitchel chief operating officer. He has more than 20 years of general management and operations experience in the medical field. For the past four years, he was a principal with the Pacific Consulting Group. Mr. Carmitchel earned a MBA from the University of Southern California and a bachelor’s degree in electrical engineering from the General Motors Institute. John R. Post InfaCare Names President and CEO John R. Post has been appointed president and CEO of InfaCare Pharmaceutical, a specialty pharmaceutical company focused on developing innovative therapies for neonates and older children. Mr. Post was named chief operating officer of InfaCare, Neptune, N.J., in June 2004. Previously, he was at Pfizer and Boehringer Ingelheim. He received his B.A. in zoology from the University of Santa Barbara. Timothy C. Tyson Valeant Pharmaceuticals Appoints President and CEO Valeant Pharmaceuticals International has named Timothy C. Tyson president and CEO. Valeant, Costa Mesa, Calif., is a research-based specialty pharmaceutical company that discovers, develops, manufactures, and markets a broad range of pharmaceutical products. Mr. Tyson previously served as Valeant’s president and chief operating officer and succeeds Robert W. O’Leary, who continues as chairman of Valeant. Leslie J. Williams Ventaira Pharmaceuticals Promotes Chief Operating Officer to President and CEO Ventaira Pharmaceuticals, a specialty pharmaceutical company, has promoted Leslie J. Williams to the position of president and CEO. Ms. Williams joined Ventaira, Columbus, Ohio, in March 2003 and most recently held the position of chief operating officer. Ms. Williams holds a MBA from Washington University, John Olin School of Business, and a B.S. degree with honors in nursing from the University of Iowa. Device/Diagnostic POOL Dr. W. Jeffrey Allard Fujirebio Diagnostics Appoints VP and Chief Scientific Officer Fujirebio Diagnostics (FDI) has appointed W. Jeffrey Allard, Ph.D., as VP and chief scientific officer. FDI, Malvern, Pa., is a diagnostics company and subsidiary of Tokyo-based Fujirebio. Dr. Allard is a biochemist and immunologist with more than 25 years of experience, and he holds eight patents for key diagnostic processes. At FDI, Dr. Allard assists in the selection process for new product candidates and their introduction into global markets. In addition, he manages FDI’s expanding global network of in-licensing institutions and promotes the company’s continuing relationships with research organizations. Dr. Allard directs FDI’s research and development, clinical/regulatory affairs, and process engineering staff. Dr. Allard previously was at Immunicon, where he was VP of clinical research and development. He holds a Ph.D. in biochemistry from Dartmouth College, a M.S. in immunology from Idaho State University, and a B.S. cum laude in preveterinary medicine from the University of New Hampshire. Sidney A. Aroesty Diagnostic Products Names President Diagnostic Products (DPC), a Los Angeles-based company focused on immunodiagnostics, has appointed Sidney A. Aroesty as president. Mr. Aroesty, 58, has been associated with DPC since 1978 and has served as a director since 1981. He previously served as senior VP, operations, and chief operating officer. As president, Mr. Aroesty is directly responsible for worldwide day-to-day operations. Martin J. Emerson American Medical Systems Names CEO American Medical Systems (AMS) has promoted Martin J. Emerson to president and CEO from president and chief operating officer. Mr. Emerson also has been appointed to the company’s board of directors. American Medical Systems, Minnetonka, Minn., is a diversified supplier of medical devices and procedures to cure erectile dysfunction, benign prostatic hyperplasia, incontinence, and other pelvic disorders in men and women. Douglas W. Kohrs, the company’s former CEO, remains as chairman of the board. Mr. Emerson has 20 years of medical-device experience and in his more than four years at AMS, has held executive roles, including VP and general manager of international, executive VP of global sales and marketing, chief operating officer, and most recently, president. Dr. Albert E. Heacox Senior R&D VP Position Filled at CryoLife CryoLife, a biomaterials and biosurgical device company, has named Albert E. Heacox, Ph.D., to the position of senior VP of research and development. Dr. Heacox, 54, joined Atlanta-based CryoLife in 1985. He completed his B.S. and M.S. degrees in biology at Adelphi University and received his Ph.D. in zoology from Washington State University. He completed his postdoctorate training in cell biology from The University of Cologne in Germany. Dr. Frederick A. Robertson TomoTherapy CEO Named TomoTherapy, Madison, Wis., a developer of medical treatment devices used in the fight against cancer, has appointed Frederick A. Robertson, M.D., MBA, as CEO. Dr. Robertson is the former CEO of Marquette Medical Systems and brings more than 20 years of medical and management experience to the company. Dr. Robertson received his M.D. from the University of Wisconsin Medical School and his MBA from San Diego State University. Scott A. Root Astra Tech Appoints New U.S. CEO Astra Tech has appointed Scott A. Root to president and CEO of Astra Tech, Waltham, Mass. Astra Tech is the U.S. subsidiary of Astra Tech AB, a developer and manufacturer of dental implants and medical devices for surgery and urology and a part of the AstraZeneca group. Mr. Root also serves on the company’s board of directors. Most recently, he was senior VP at Straumann USA. He has a B.S. in business administration from Babson College. Discovery POOL Dr. Craig Saxton Chairman of Neurogen Appointed Neurogen, Branford, Conn., a drug-discovery and development company, has named Craig Saxton, M.D., as chairman of the board. Dr. Saxton, 62, is a former executive of Pfizer, where he most recently was responsible for global drug development. Dr. Saxton has served on Neurogen’s board since January 2002 and succeeds Frank C. Carlucci, who has retired as Neurogen’s chairman after 15 years of service. Mr. Carlucci has been appointed as chairman emeritus. Dr. Saxton earned a B.S. in anatomy and a M.D. from Leeds University, United Kingdom. He is a member of the scientific board of the U.S. branch of the African Medical and Research Foundation, a member of the American Academy of Pharmaceutical Physicians, and the Connecticut Academy of Science and Engineering. Genomics POOL David Ichikawa Sangamo BioSciences Appoints Senior VP, Business Development Sangamo BioSciences has appointed David Ichikawa as senior VP of business development. Sangamo BioSciences, Richmond, Calif., is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. Mr. Ichikawa has responsibility for all licensing and business development activities for the company. Most recently, he was chief business officer for Sagres Discovery. Mr. Ichikawa has a MBA from the University of California at Berkeley and a B.S. degree from the University of California at Davis. Emerging POOL Dr. David Fry Dr. Peter Lenehan Genetics Squared Fills Scientific Leadership Positions Ann Arbor, Mich.-based Genetics Squared has named David Fry, Ph.D., chief science officer, and Peter Lenehan, M.D., Ph.D., as chief medical officer. Genetics Squared is an emerging biotechnology company focused on delivering the promise of personalized medicine. Dr. Fry had been an active member of Genetics Squared’s scientific advisory board. He leads the discovery of appropriate biomarkers and combinations of biomarkers to identify the optimal patient population for drugs in-licensed by the company for redevelopment. Dr. Lenehan is responsible for the acquisition and clinical development of promising but struggling clinical oncology compounds. Most recently, he was director of clinical oncology at Pfizer, where he led the early clinical development of many cancer therapies for solid tumors. He received a Ph.D. and M.D. from SUNY Downstate Medical Center. Ronald D. Henriksen Semafore Creates CEO Position Semafore Pharmaceuticals, Indianapolis, which focuses on developing small-molecule cancer therapies that address PI3K and PTEN cell-signaling pathways, has named Ronald D. Henriksen CEO, a newly created position. Mr. Henriksen has 35 years of experience as a life-sciences industry executive, entrepreneur, and investor. Currently, he is chief investment officer of Twilight Ventures Partners, a life-sciences venture capital firm that he cofounded. He earned a B.S. from Iowa State University and a MBA with distinction from Harvard Business School. Association POOL Rabia Akram Sue Ann Capizzi AMA Division Adds to Staff The American Medical Association (AMA) Division of Continuing Physician Professional Development (CPPD), Chicago, has added to its staff. Rabia Akram has joined CPPD as program administrator for AMA PRA Policy. She has a background in public health, having recently served as program coordinator for an immunization community outreach initiative with Mount Sinai Hospital. She received her MPH and MBA from the University of Illinois at Chicago. Sue Ann Capizzi has joined CPPD as assistant division director and director of CME strategic business development. She is a surveyor for both the ISMS and the ACCME. She is a member of the national task force on CME Provider/Industry Collaboration, and she served as chairperson of the 15th Annual Conference of the National Task Force on CME Provider/Industry Collaboration. Ms. Capizzi also is a member of the board of directors of the Alliance for CME, where she is also the treasurer-elect. Charles Craig Georgia Biomedical Partnership Names President The Georgia Biomedical Partnership (GBP) has named Charles Craig as president. The GBP, Atlanta, represents the life-sciences industry in Georgia. Mr. Craig has been involved in the life-sciences industry for 10 years. He previously was the author and editor of Ernst & Young’s Global Biotechnology Reports and is former director of publications for the Biotechnology Industry Organization. He has a bachelor of arts degree from the University of Virginia and master of journalism degree from Louisiana State University. David Johnson BioCrossroads Names CEO BioCrossroads, Indiana’s life-sciences initiative, has appointed David Johnson as CEO. Mr. Johnson is a partner of the Indianapolis law firm Baker & Daniels. He replaces Charles Schalliol. As one of the original four members of the life-sciences committee that developed the concept for the formation of BioCrossroads, Mr. Johnson was an early promoter of the initiative, serving as chairman of its capital formation task force and leading the development of the Indiana Future Fund. He continues the effort to create the Indiana Seed Fund, an early-stage venture capital fund aimed at promising Indiana life-sciences opportunities. Mr. Johnson graduated from Harvard University and Harvard Law School, and he studied at Oxford University as a Rhodes Scholar. Agency POOL Dr. Robert Caspari Jennifer Hastings Larry Sanata Tara Shade Jeff Tobin Stonefly Communications Group Announces New Hires Stonefly Communications Group, a customer-centric advertising agency based in Westerville, Ohio, and a subsidiary of inChord Communications, has announced staff additions. Robert Caspari, M.D., has been named medical director. He is responsible for providing strategic medical and scientific oversight on all of Stonefly’s pharmaceutical accounts. Before joining Stonefly, Dr. Caspari served as VP and general manager of biopharmaceuticals at Novo Nordisk Pharmaceuticals. He holds a degree in medicine from Georgetown University and a bachelor’s degree from UCLA. Jennifer Hastings has been named creative project manager. She is responsible for coordinating creative production and managing the overall quality, deadlines, and budgets. Before joining Stonefly, Ms. Hastings served as print and traffic coordinator at Franklin University. She holds a master’s degree and bachelor’s degree from Franklin University. Larry Sanata has been named healthcare copy specialist. He is responsible for writing and creating copy for Stonefly’s pharmaceutical accounts. Before joining Stonefly, Mr. Sanata was a freelance public relations and marketing writer. He holds a bachelor’s degree from Youngstown State University. Tara Shade has been named senior art director. She is responsible for brand concepts, design, presentation, execution, and production for all projects. Ms. Shade had been the co-owner/art director at the design firm, The Rivets. She holds a bachelor’s degree from The Art Institute of Pittsburgh. Jeff Tobin has been named associate creative director. He is responsible for overseeing all creative developments for Stonefly’s accounts. Before joining Stonefly, Mr. Tobin served as senior VP/creative director at Chernoff-Silver & Associates. He holds a bachelor’s degree from Florida State University. Steve Cragle Amber Poland Joe Soto Dorland Creates New Positions Dorland Global Health Communications, with headquarters in Philadelphia, has made new additions to its San Francisco office. Steve Cragle has joined the agency as VP of public relations to oversee all public-relations activities on the West Coast. Previously, Mr. Cragle was senior VP at Schwartz Communications. Amber Poland has joined the agency as senior account supervisor. Previously, she worked at Giant and FCB. Joe Soto has been named general manager. Mr. Soto joined Dorland a year ago as executive VP. In this new capacity, Mr. Soto is responsible for supervising all operations of the California office on a day-to-day basis. The general manager position was created in response to major changes that have occurred in the San Francisco office over the past year, including the relocation of the office, doubling of the staff, and addition of new clients and services. Analia Del Giorgio Bruce Weinberg Palio Fills Graphic Designer and Copywriter Positions Palio Communications, a full-spectrum advertising and communications agency based in Saratoga Springs, N.Y., and a unit of inChord Communications, has appointed Analia Del Giorgio as senior graphic designer and Bruce Weinberg as senior copywriter. Ms. Del Giorgio has eight years of graphic design experience, previously serving as a freelance graphic designer for several academic and corporate clients. Mr. Weinberg brings brand development and marketing skills to his role at Palio. Previously, he was owner and creative director at @WAO Creative. He holds a B.S. from American University and certification from New York University’s Center for Direct Marketing. Carleen Kelly Corbett Accel Appoints President of New York Advertising Corbett Accel Healthcare Group has appointed Carleen Kelly to lead its New York advertising team as its president. Ms. Kelly replaces Richard Nordstrom, who has left the agency. Ms. Kelly joined Corbett Accel — New York in March 2004 to help direct the agency’s growth. Previously, she served as executive VP and chief operating officer for Torre Lazur McCann Healthcare Worldwide. She has a bachelor’s degree in marketing from St. John’s University in New York. Michael Ouimette Torre Lazur West Names President Michael Ouimette has been appointed president of Torre Lazur West, San Diego. Formerly known as the BioGenesis Group, the agency is a division of Torre Lazur McCann. Mr. Ouimette brings 30 years of pharmaceutical marketing experience to the agency. As president, he is responsible for the overall management and new business development. He joins the agency after 10 years at Pacific Communications, where he was senior VP for client services. Mr. Ouimette is a graduate of Western Connecticut State College. Dr. John Tapper Ziment Names Chief Strategy Officer John Tapper, Ph.D., has been appointed chief strategy officer of The Ziment Group, a consortium of healthcare and pharmaceutical market-research companies with headquarters in New York. Previously, Dr. Tapper was responsible for helping set strategic direction for the group, as well as for product development for the company’s imap research division, which focuses on conducting multiclient studies for healthcare and pharmaceutical clients. Media POOL Dr. Ho-Leung Fung AAPS Journal Names Editor-in-Chief Ho-Leung Fung, Ph.D., has been named editor-in-chief of The AAPS Journal, the American Association of Pharmaceutical Scientists’ (AAPS) peer-reviewed, online open-access publication covering the topics of drug discovery, development, and therapy. AAPS, Arlington, Va., is a professional, scientific society of more than 12,000 members employed in academia, industry, government, and other research institutes worldwide. Dr. Fung is professor, department of pharmaceutical sciences, and AAPS student chapter faculty advisor at the University at Buffalo. He is a fellow of AAPS, the American Association for the Advancement of Science, and the Academy of Pharmaceutical Scientists. Dr. Fung has published more than 200 papers on his research interests. Dr. Fung takes over for Wolfgang Sadée, Dr.rer.nat., who served as editor-in-chief of The AAPS Journal since its inception in 1988. Medical-Education POOL Dr. Richard Avenia ProCom Selects Medical Director ProCom International, a CommonHealth medical-education unit based in Parsippany, N.J., has appointed Richard Avenia, Ph.D., MBA., R.Ph., as medical director. In this role, Dr. Avenia draws on his experience in both the medical and healthcare communications fields to assist in the development of medical-education materials and to review and write educational content for assigned accounts. Dr. Avenia graduated magna cum laude with a B.S. degree from St. John’s University College of Pharmacy. In addition, he holds a master’s degree in business management from Fairleigh Dickinson University and a Ph.D. in biochemical pharmacology and drug metabolism from Cornell University Graduate School of Medical Sciences. Service POOL Dr. Geoffrey R. Barker Dr. Charles Hsu A. M. Pappas Names Executive-in-Residence and Venture Partner A. M. Pappas & Associates (AMP&A), a life-sciences venture capital firm, has named Geoffrey R. Barker, M.D. as an executive-in-residence, and Charles Hsu, Ph.D., has been named as a venture partner. Dr. Barker provides clinical-development support to the firm’s portfolio companies and assists in assessing potential portfolio companies’ clinical and regulatory programs. Dr. Barker began working with AMP&A in mid-2004 and is based in the firm’s Research Triangle Park, N.C., headquarters. Dr. Barker has held senior executive, medical, scientific, and clinical positions with Astra, Actelion Pharmaceuticals, and Quintiles Transnational, where he most recently served as chief medical and scientific officer. Dr. Barker is a U.K.-qualified physician and is a fellow of the Royal College of Pharmaceutical Physicians, a fellow of the Royal Colleges of Surgeons, and a fellow of the Royal College of Dental Surgeons. He is an adjunct professor in immunology at Duke University Medical School. Dr. Hsu, based in San Francisco, focuses on identifying and evaluating new life-sciences investment opportunities in California and elsewhere on the West Coast. Dr. Hsu is the company’s third venture partner, and he has been an active venture capital investor since 1990. Dr. Hsu is a director of Asia Renal Care, the leading independent dialysis services company in Asia, of which he was a cofounding investor, and he is chairman of Eureka! Pharmaceuticals. Dr. Hsu received his AB in biochemistry from Harvard University and his Ph.D. and MBA from Stanford University. Leanne Davis John Loughran Karima Sharif CMI Announces Promotions Communications Media (CMI), an advertising media and promotions planning company, has promoted Leanne Davis to media account supervisor from senior media planner. Since early August, Ms. Davis has been operational head of the King of Prussia, Pa.–based company. Ms. Davis joined CMI in March 2004. In addition, CMI has promoted John Loughran to assistant media planner I. Mr. Loughran is working on the Arimidex, Faslodex, Casodex, Zoladex, and Seroquel accounts for AstraZeneca. Karima Sharif has been promoted to senior media planner at CMI Philadelphia. Ms. Sharif has worked at CMI Philadelphia for the past five years. Daphne Ewing Octagon Names Clinical Data Operations VP Octagon Research Solutions, a King of Prussia, Pa.-based provider of process-centric solutions to the life-sciences industry, has named Daphne Ewing VP, clinical data operations, which comprises clinical data management, programming, statistics, and medical writing functions. She brings more than 18 years of contract services industry experience to the position and is charged with institutionalizing best practices that support Octagon’s holistic approach to producing submission deliverables. Giovanni A. Ferrara Bryant E. Fong Richard T. Haiduck David Haselwood Stephen M. Kujawa Rizwan Velji James D. Watson Burrill Announces Promotions Burrill & Company, a San Francisco-based life-sciences merchant bank, has named Giovanni A. Ferrara as managing director. He has more than seven years of experience in venture capital in the biopharmaceutical industry. Mr. Ferrara has academic training in molecular biology. Bryant E. Fong has been promoted to principal. He has more than 10 years of health-science experience in the areas of molecular biology, genetic engineering, partnering and alliances, and direct investing. Richard T. Haiduck has been promoted to managing director. His life-sciences experience spans 25 years, including seven years as a biotech dealmaker at both the VP and CEO level at Geron and Desmos. David Haselwood has been promoted to senior associate. Previously, he worked in the healthcare investment banking departments of Volpe Brown Whelan & Co. and Prudential Securities. Stephen M. Kujawa has been named director of business development. Previously, he was in new product development and management at Incyte Genomics. Rizwan Velji has been named senior associate. Previously, he was at the Human Molecular Genetics Department at Baylor College of Medicine, where he served as research assistant with the Adenoviral Vector Gene Therapy Group. James D. Watson has been named managing director. He has experience across therapeutics and technology and has led numerous acquisitions and collaborations, launched major products, and built a management consulting practice. In addition, Mr. Watson assumes the role of merchant banking practice head, leading the growth and coordination of the strategic partnering, advisory, and M&A components of the merchant banking practice. In other company news, Ann Hanham, John Kim, Roger Wyse, Mike Ullman, John Haag, and Tim Young have been named as general partners in the Burrill Life Sciences Capital Fund III. Shelli Field TVG President Named Shelli Field has been named president of TVG, a marketing research and consulting business unit of PDI, Saddle River, N.J. She joined TVG in 2002 as an executive VP and member of the company’s guiding executive committee. Her career experience includes more than two decades as a marketing and marketing research professional. Please send your personnel announcements to [email protected]. PHARMACEUTICAL INDUSTRY CREATIVE GIANT DIESJohn MacVean Lally John MacVean Lally, 68, one of the pharmaceutical industry’s long-term creative talents, passed away Jan. 22, 2005, from a heart attack. Mr. Lally was a founding partner of Lally, McFarland & Pantello, now a part of the Euro RSCG Life network of healthcare agencies. He was a resident of Killingworth, Conn., where he lived until his death. “John will be remembered for his humor, passion for the creative product and staff, and legendary genius,” commented Ron Pantello, CEO of Euro RSCG Life. “He was unquestionably the greatest copywriter and creative director of his generation.” Mr. Lally began his medical advertising career as a copywriter at William Douglas McAdams and Robert A. Becker Advertising. In what was a career-defining move, Mr. Lally joined Sudler & Hennessey, where he focused on what he liked to do best — creating effective market positioning for products in concert with the creative expressions of those positions. His approach was to immerse himself in a product’s clinical and technical literature, analyze the competition, the market, and clinical practice in depth, then, using his considerable capacity for retaining detail and his scientific background, bring all of the factual threads together. At S&H, where he became creative director, his analytical and creative thinking helped such products as Premarin and Inderal achieve record sales. In 1980, he left S&H with James McFarland and Ron Pantello to found Lally McFarland & Pantello, where he continued to serve as marketing strategist and creative director for such clients as Ayerst, Norwich, Procter & Gamble, and Wyeth. Mr. Lally was known for his marketing insights and facile, erudite manner. Lally McFarland & Pantello was acquired by Euro RSCG in 1989. Mr. Lally retired in 1993, and he continued to pursue his love of baseball and American history. He graduated from Colgate University, with a B.S. degree in chemistry, and obtained a postgraduate degree in mathematics from Syracuse University. Mr. Lally also studied concert piano at Julliard School of Music.

Download PDF